Intelligence · Clinical Pipeline
Acadia Pharmaceuticals Pipeline
All ClinicalTrials.gov programs at Acadia Pharmaceuticals — phase, modality, and trial IDs.
- Programs
- 4
Quick answer
Acadia Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
L. helveticus R0052 and B. longum R0175
Acadia Pharmaceuticals B.V.
Attention Deficit Hyperactivity Disorder
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Insomnia Chronic
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Neurodegenerative Diseases
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Parkinson Disease Psychosis
1 trial
Frequently asked questions
How many pipeline programs does Acadia Pharmaceuticals have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs